Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

Active, not recruitingOBSERVATIONAL
Enrollment

274

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Osimertinib

Single arm treated by osimertinib

Trial Locations (46)

Unknown

Research Site, Abbeville

Research Site, Aix-en-Provence

Research Site, Angers

Research Site, Antibes

Research Site, Avignon

Research Site, Bastia

Research Site, Bayonne

Research Site, Bordeaux

Research Site, Bourg-en-Bresse

Research Site, Brest

Research Site, Cannes

Research Site, Chambéry

Research Site, Chauny

Research Site, Cholet

Research Site, Clermont-Ferrand

Research Site, Colmar

Research Site, Contamine-sur-Arve

Research Site, Créteil

Research Site, Elbeuf

Research Site, Epagny METZ Tessy

Research Site, Évreux

Research Site, La Roche-sur-Yon

Research Site, Libourne

Research Site, Limoges

Research Site, Lyon

Research Site, Marseille

Research Site, Meaux

Research Site, Mulhouse

Research Site, Orléans

Research Site, Paris

Research Site, Poitiers

Research Site, Quimper

Research Site, Reims

Research Site, Rouen

Research Site, Saint-Denis

Research Site, Saint-Grégoire

Research Site, Saint-Pierre

Research Site, Saint-Priest-en-Jarez

Research Site, Saint-Quentin

Research Site, Toulon

Research Site, Toulouse

Research Site, Valenciennes

Research Site, Vannes

Research Site, Villefranche-sur-Saône

Research Site, Villenave-dornon

Research Site, Villeurbanne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY